Fexuprazan is under clinical development by Daewoong and currently in Phase II for Helicobacter pylori Infections. According to GlobalData, Phase II drugs for Helicobacter pylori Infections have a 64% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Fexuprazan’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Fexuprazan overview
Fexuprazan (Fexuprazan Hydrochloride, Fexuclu, Abcito) is a P-CAB (Potassium-Competitive) Acid Blocker). It is formulated as film-coated tablets for oral route of administration. It is indicated for the treatment of erosive gastroesophageal reflux disease.
Fexuprazan (DWP-14012) is under development for the treatment of acute or chronic gastritis, gastric ulcers, helicobacter pylori infections, erosive esophagitis and erosive gastroesophageal reflux disease. It is a small molecule which is administered by oral route in the form of tablet and as injection form. It acts by targeting the acid pump, H+/K(+) ATPase. The drug candidate is a potassium-competitive acid blocker (P-CAB).
Daewoong overview
Daewoong is an investment holding company. It offers services including investment services and financial services and others. The company also operates in the manufacture of pharmaceutical products, food processing, enterprise education solutions, information technology (IT) solutions, and pharmaceutical raw materials among others. The company its products and services through its subsidiaries such as Daewoong Pharmaceutical Co., Ltd and R&P Korea Co., Ltd, Daewoong Life Science Co., Ltd., Daewoong Management Development Institute, IDS&TRUST Co., Ltd. and Deawoong Bio Co., Ltd. It operates across south Korea. Daewoong is headquartered in Seoul, South Korea.
For a complete picture of Fexuprazan’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
